Status: Recruiting
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
This Phase 3, randomized, double-blind, parallel-group (2-arm), placebo-controlled, multicenter study will evaluate the efficacy and safety of NNZ-2591 compared to placebo in pediatric participants with Phelan- McDermid Syndrome.
Participants needed: 160
Trial details
Phase: Phase 3Age: 3-12Biological sex: AllType: InterventionalSponsor: Neuren Pharmaceuticals LimitedUpdated: Aug 25, 2026Locations: 15
Eligibility criteria
Male or female pediatric participants with Phelan-McDermid syndrome ages 3 to 12... [+4]
Use of exclusionary medication or unstable treatment regimens of acceptable conc... [+6]